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ABSTRACT
Antibiotic resistance among Gram-positive bacteria has increased relentlessly in recent years, thereby
compromising the use of traditional therapies. In the hospital setting, multidrug-resistant pathogens,
particularly methicillin-resistant Staphylococcus aureus (MRSA) and emerging vancomycin-resistant
pathogens, cause serious infections and create a substantial financial burden. Perhaps of greater concern
are the increasingly frequent reports of community-acquired MRSA (CA-MRSA). As the present
distinction between CA-MRSA and hospital-acquired MRSA (HA-MRSA) begins to blur, the predicted
consequences of CA-MRSA include endemic infection within the community and a potential further
increase in the burden of nosocomial infection. Reducing the spread of antimicrobial resistance will
require worldwide cooperation. Regulatory authorities have already been established in a number of
countries to implement infection prevention and infection control initiatives. Complementary to such
measures in the management of infectious disease is the development of novel therapeutic agents.
Newly approved agents, such as daptomycin, are welcome additions to the increasingly narrow range of
effective therapies.
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INTRODUCTION
Over the past 25 years, there has been a steady and
unrelenting increase in antibiotic resistance, par-
ticularly among Gram-positive bacteria. The emer-
gence of pathogens such as vancomycin-resistant
enterococci (VRE), multidrug-resistant coagulase-
negative staphylococci (CoNS) and methicillin-
resistant Staphylococcus aureus (MRSA) has had a
significant impact on patterns of prescribing and
created a substantial economic burden.
The glycopeptides have been the ‘gold stand-
ard’ treatment for Gram-positive infections for
over 40 years, due to their broad spectrum of
activity, favourable pharmacokinetics and accept-
able safety profiles [1]. However, in recent years,
there has been a rapid increase in the appearance
of high-level vancomycin resistance in enterococci
[2], together with the emergence of vancomycin-
intermediate and -resistant S. aureus (VISA and
VRSA) [3]. These strains are usually also cross-
resistant to teicoplanin, further compromising
glycopeptide use [4].
There is now an urgent need both to introduce
control measures to slow the spread of antimi-
crobial resistance and to develop therapeutic
agents with activity against newly emerging
drug-resistant Gram-positive pathogens. Agents
recently approved for clinical use that show
particular promise include: linezolid, the first of
the oxazolidinones; daptomycin, the first of the
cyclic lipopeptides; and telithromycin, a ketolide
derived from clarithromycin.
This review examines several clinically import-
ant Gram-positive pathogens, outlines strategies
for controlling antimicrobial resistance, and dis-
cusses current and future treatment options for
Gram-positive infections.
CLINICALLY IMPORTANT DRUG-
RESISTANT GRAM-POSITIVE
PATHOGENS
Vancomycin-resistant enterococci
Resistance to vancomycin in enterococci was first
reported in Europe in 1988 [5]. Since then, VRE
have emerged as important nosocomial pathogens,
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particularly in the USA, where 28.5% of all isolates
were resistant to vancomycin in 2003 [6]. In
Europe, the incidence of VRE remains very low in
most countries: 0.9% of Enterococcus faecalis and
9% of Enterococcus faecium isolates were fully
resistant to vancomycin across thewhole of Europe
in 2004 [7]. ManyVRE isolates also show resistance
to teicoplanin as well as to aminoglycosides and b-
lactams [8,9]. As a result, therapeutic options for
serious VRE infections are limited [10,11]. The
ability of enterococci to transfer antibiotic resist-
ance to more serious pathogens, such as S. aureus,
has already been demonstrated by recent reports of
the transfer of the VanA gene cluster from VRE to
MRSA in two patients in the USA [12,13]. Such
reports serve to highlight the potential dangers of
coexisting reservoirs of both pathogens.
Coagulase-negative staphylococci
CoNS are important pathogens in the hospital
environment and are commonly responsible for
biofilm formation on medical devices, such as
prosthetic heart valves and intravascular catheters.
CoNS were the first organisms in which acquired
glycopeptide resistance was recognised [14]; re-
ports suggest that resistance to teicoplanin is more
common than to vancomycin and occurs mostly in
Staphylococcus haemolyticus and Staphylococcus epi-
dermidis [14]. In addition, approximately 75% of
CoNS isolates are also resistant to oxacillin [15].
Alternative agents for the treatment of CoNS
biofilm-associated device infections include rifam-
pin,minocycline and,more recently, quinupristin–
dalfopristin and the oxazolidinones [16].
Methicillin-resistant Staphylococcus aureus
Over recent years, MRSA has emerged as the
predominant nosocomial Gram-positive pathogen
and is thought to be involved in >50% of hospital
S. aureus infections [17]. In Europe, MRSA pre-
valence rates vary between countries, with the
UK, Ireland and Greece having among the highest
rates (44%, 41% and 44%, respectively, in 2004)
[7]. There have also been substantial increases in
MRSA prevalence in other countries, including
Italy and Belgium (Fig. 1) [7]. Even in northern
Europe, where rates are lower (e.g., The Nether-
lands and Denmark), there has been a trend
towards slight increases [7], and it is expected that
these countries will show further steady increases
in the future.
Together with a broad resistance to all b-
lactams, MRSA strains often possess multidrug
resistance to cephalosporins, aminoglycosides,
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Fig. 1. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in eight European countries from 1999 to 2004 [7].
Arrows indicate significant trends.
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fluoroquinolones and macrolides [17]. Further-
more, MRSA infections are associated with con-
siderable morbidity and mortality and are more
costly to manage than other types of infection [18–
20]. These additional expenses arise from pro-
longed hospitalisation, increased isolation care,
extra screening requirements and the added
financial burden of second-line therapy. It has
been estimated that the annual cost of MRSA
infections to US hospitals is $3.2–4.2 billion
(E. Rojas and L. Liu, ISPOR 2005).
Hospital- and community-acquired MRSA
Until recently, most MRSA infections have been
hospital-acquired (HA-MRSA). A number of risk-
factors have been shown to predispose a patient
to acquire HA-MRSA. These include recent hos-
pitalisation, residence in long-term care facilities,
treatment in an intensive care unit, prolonged
antimicrobial therapy, invasive or surgical proce-
dures, and contact with a patient infected or
colonised with MRSA [21,22].
Since the early 1990s, community-acquired
MRSA (CA-MRSA) infections have appeared with
increasing frequency in many parts of the world,
most notably the USA, Australia and New Zea-
land [23–25]. CA-MRSA often occurs in healthy
patients without the typical risk-factors for HA-
MRSA acquisition [23]. In the USA, the percent-
age of CA-MRSA-related cases increased from 7%
in 1993 to 29% in 1999 in San Francisco General
Hospital and associated clinics, and continues to
increase [26].
The relationship between CA-MRSA and HA-
MRSA is illustrated in Fig. 2. It can be seen that
CA-MRSA strains differ from HA-MRSA strains
in both their antibiotic susceptibilities and genetic
backgrounds [21]. CA-MRSA strains harbour the
methicillin resistance cassette SCCmec type IV
element, characterised by its small size and
absence of antibiotic resistance markers. This is
consistent with the finding that many CA-MRSA
strains are highly susceptible to antibiotics, with
resistance often limited to the b-lactams, unlike
HA-MRSA strains, which are usually multidrug
resistant. Also present are the genes encoding
Panton–Valentine leukocidin, a virulence factor
associated with skin and soft tissue infections as
well as more serious infections (e.g., severe
necrotising pneumonia) [27]. It is anticipated that
the present distinction between CA- and HA-
MRSA may begin to blur in the future [28].
Multidrug-resistant CA-MRSA isolates have
already been reported [29], while genetic analysis
of CA-MRSA has revealed that certain clones are
found in both the community and hospital envi-
ronments [21]. As shown in Fig. 2, nursing homes
are considered to be a potential source of both
CA- and HA-MRSA, and may provide a further
link between the two. The therapeutic implication
of serious HA-MRSA and CA-MRSA arising in
nursing homes is of concern, since currently,
parenteral antibiotic treatment is required for
their management.
Prevalence of CA-MRSA
Reported prevalence rates for CA-MRSA vary
widely [30]. A recent worldwide meta-analysis
found a pooled MRSA colonisation rate of 0.2%
among community members without healthcare
contacts [31]. Other reports suggest that rates may
be as high as 42% among members of closed
populations, such as Canadian and Australian
Aboriginal communities and Pacific Islanders
[32,33]. These higher rates of CA-MRSA may be
associated with risk-factors for the spread of
infection in the community, such as overcrowd-
ing, high rates of skin infections and frequent use
of broad-spectrum antibiotics [34].
To date, few studies have assessed the epi-
demiology of CA-MRSA in Europe [35]. The
limited data that are available indicate that the
Fig. 2. Relationship between community- and hospital-
acquired methicillin-resistant Staphylococcus aureus
(MRSA), illustrating the dynamics between the two and
the importance of nursing homes as an additional source of
infections. PVL, Panton–Valentine leukocidin; SSTI, skin
and soft tissue infection.
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prevalence of CA-MRSA remains relatively low in
the community. For example, in a retrospective
study performed in a hospital in France between
January 2001 and September 2003, an incidence of
0.8% was recorded [36]. In Switzerland, two case
studies involving 14 253 patients estimated the
prevalence of CA-MRSA upon admission to
hospital to be 0.1% [35].
CONTROL OF ANTIMICROBIAL
RESISTANCE
In recent years, there have been concerted efforts
worldwide to slow the emergence and spread of
antimicrobial resistance and reduce healthcare-
associated infection. A number of common strat-
egies have been employed, which include:
(i) increasing surveillance of antibiotic resistance;
(ii) better surveillance of drug usage; (iii) improv-
ing health education for both prescribers and
patients; (iv) ensuring that all prescribing is pru-
dent; (v) improving hygiene and general measures
to prevent cross-infection; and (vi) developing new
drugs and new technologies (including anti-infec-
tives, vaccines and better diagnostics).
Regulatory authorities have been established in
many countries to implement control programmes
and provide support and guidance. In theUSA, the
CDC have established the National Nosocomial
Infections Surveillance (NNIS) System and Active
Bacterial Core surveillance (ABCs), together with
the Campaign for Appropriate Antibiotic Use and
the Campaign to Prevent Antimicrobial Resistance
in Healthcare Settings [37,38]. In Australia, the role
of the Expert Advisory Group on Antimicrobial
Resistance (EAGAR) is to provide advice on meas-
ures to reduce the risk of antimicrobial resistance,
while in the UK, the Specialist Advisory Commit-
tee on Antimicrobial Resistance (SACAR) fulfils
this role [39,40].
The European Centre for Disease Prevention
and Control (ECDC) was set up in October 2005
with an action plan that includes surveillance,
guideline development, facilitation of preven-
tion ⁄ control of healthcare-associated infection
and country support [40,41]. In the UK, efforts
to control the spread of MRSA have so far been
unsuccessful, resulting in considerable public
and political concern [42]. In October 2005, the
UK Department of Health responded to these
concerns by introducing the Mandatory Bacter-
aemia Surveillance Scheme. This requires the
mandatory reporting of all MRSA blood culture
isolates and has set a target to reduce MRSA by
50% by 2008. In addition, the British Society for
Antimicrobial Chemotherapy, Hospital Infection
Society and Infection Control Nurses Associ-
ation have also produced guidelines for the
prophylaxis and treatment of MRSA in the UK
[43].
THERAPEUTIC AGENTS FOR GRAM-
POSITIVE INFECTIONS: WHAT ARE
THE OPTIONS?
The glycopeptides vancomycin and teicoplanin
have significant activity against Gram-positive
pathogens. Although teicoplanin has not been
approved for use in the USA, vancomycin is
widely used for the treatment of staphylococcal
and enterococcal infections. However, concerns
have recently been raised about the efficacy of
vancomycin, due to increasing MICs among
staphylococci, poor tissue penetration and a
slower rate of bacterial killing than was previ-
ously recognised [44]. The cross-resistance shown
by many isolates to teicoplanin has limited the use
of this as an alternative agent [4].
There is clearly an unmet need for new thera-
peutic agents for the treatment of infections
caused by resistant Gram-positive organisms.
Among the newer agents recently approved for
clinical use are daptomycin, linezolid and teli-
thromycin. Daptomycin, the first of a new class,
the cyclic lipopeptides, has broad spectrum and
rapid bactericidal activity against Gram-positive
bacteria, including MRSA, CoNS and VRE [45–
47]. Daptomycin is indicated for the treatment
of skin and soft tissue infections but has also
been used successfully in clinical trials for
S. aureus bacteraemia and infective endocarditis
[48].
Linezolid, the first of the oxazolidinones, has a
spectrum of activity against virtually all Gram-
positive pathogens [49]. Linezolid is indicated
for the treatment of community-acquired and
nosocomial infections, and infections caused by
MRSA and VRE, including cases with concurrent
bacteraemia [49].
Telithromycin is the first of the ketolides, a new
subclass of macrolides. Telithromycin shows
good in vitro activity against most Gram-positive
bacteria, including methicillin-sensitive S. aureus,
but lacks activity against MRSA [50]. It may be
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used for the treatment of mild-to-moderate com-
munity-acquired respiratory infections such as
community-acquired pneumonia and acute sinus-
itis.
Agents currently in clinical development in-
clude: the new glycopeptides dalbavancin,
oritavancin and telavancin; tigecycline, a broad-
spectrum intravenous tetracycline; ceftobiprole, a
broad-spectrum cephalosporin with activity
against MRSA; and iclaprim, a diaminopyrimi-
dine.
CONCLUSIONS
The emergence of multidrug-resistant Gram-pos-
itive pathogens is of major clinical concern.
Measures to control resistance have already been
introduced in a number of countries, including
the UK, USA and Australia. However, worldwide
cooperation will be required if such programmes
are to be successful. In the meantime, monitoring
of resistance patterns will continue to play a vital
role in reducing the emergence and spread of
resistance. Of equal importance is the need to
develop new classes of therapeutic agents that are
effective against organisms such as MRSA, VISA
and VRSA.
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